Ubs Group Ag Immuno Gen, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
SELL
$12.46 - $29.95 $136,848 - $328,940
-10,983 Reduced 5.18%
201,197 $5.97 Million
Q3 2023

Nov 09, 2023
BUY
$14.09 - $19.87 $1.07 Million - $1.52 Million
76,249 Added 56.09%
212,180 $3.37 Million
Q2 2023

Aug 11, 2023
SELL
$3.75 - $20.05 $1.54 Million - $8.22 Million
-410,171 Reduced 75.11%
135,931 $2.57 Million
Q1 2023

May 12, 2023
SELL
$3.67 - $4.92 $1.47 Million - $1.97 Million
-399,586 Reduced 42.25%
546,102 $2.1 Million
Q4 2022

Feb 08, 2023
BUY
$4.55 - $6.31 $3.64 Million - $5.05 Million
800,497 Added 551.34%
945,688 $4.69 Million
Q3 2022

Nov 10, 2022
SELL
$4.48 - $6.47 $228,462 - $329,944
-50,996 Reduced 25.99%
145,191 $694,000
Q2 2022

Aug 10, 2022
SELL
$3.15 - $5.76 $1.2 Million - $2.2 Million
-382,315 Reduced 66.09%
196,187 $883,000
Q1 2022

May 16, 2022
BUY
$4.26 - $7.48 $1.18 Million - $2.07 Million
276,405 Added 91.5%
578,502 $2.75 Million
Q4 2021

Feb 14, 2022
BUY
$4.75 - $7.5 $1.35 Million - $2.13 Million
283,972 Added 1566.74%
302,097 $2.24 Million
Q3 2021

Nov 15, 2021
SELL
$5.02 - $6.59 $242,099 - $317,815
-48,227 Reduced 72.68%
18,125 $103,000
Q2 2021

Aug 13, 2021
SELL
$5.79 - $8.6 $950,665 - $1.41 Million
-164,191 Reduced 71.22%
66,352 $437,000
Q1 2021

May 12, 2021
BUY
$6.5 - $10.53 $1.39 Million - $2.26 Million
214,523 Added 1339.09%
230,543 $1.87 Million
Q4 2020

Feb 11, 2021
SELL
$3.7 - $7.66 $2,042 - $4,228
-552 Reduced 3.33%
16,020 $103,000
Q3 2020

Nov 12, 2020
SELL
$3.45 - $4.89 $64,414 - $91,301
-18,671 Reduced 52.98%
16,572 $60,000
Q2 2020

Jul 31, 2020
SELL
$3.32 - $5.34 $293,395 - $471,906
-88,372 Reduced 71.49%
35,243 $162,000
Q1 2020

May 01, 2020
SELL
$2.12 - $6.8 $185,896 - $596,271
-87,687 Reduced 41.5%
123,615 $422,000
Q4 2019

Feb 14, 2020
SELL
$2.25 - $5.8 $506,949 - $1.31 Million
-225,311 Reduced 51.6%
211,302 $1.08 Million
Q3 2019

Nov 14, 2019
BUY
$2.22 - $3.39 $771,123 - $1.18 Million
347,353 Added 389.15%
436,613 $1.06 Million
Q2 2019

Aug 14, 2019
SELL
$1.8 - $3.3 $66,582 - $122,067
-36,990 Reduced 29.3%
89,260 $194,000
Q1 2019

May 14, 2019
SELL
$2.41 - $5.91 $541,187 - $1.33 Million
-224,559 Reduced 64.01%
126,250 $342,000
Q4 2018

Feb 14, 2019
BUY
$3.94 - $9.7 $728,198 - $1.79 Million
184,822 Added 111.35%
350,809 $1.68 Million
Q3 2018

Nov 14, 2018
BUY
$8.6 - $11.26 $577,326 - $755,895
67,131 Added 67.91%
165,987 $1.57 Million
Q2 2018

Aug 14, 2018
SELL
$9.52 - $12.15 $3.59 Million - $4.59 Million
-377,467 Reduced 79.25%
98,856 $962,000
Q1 2018

May 15, 2018
BUY
$6.7 - $12.95 $2.49 Million - $4.82 Million
371,886 Added 356.09%
476,323 $5.01 Million
Q4 2017

Feb 14, 2018
SELL
$5.07 - $7.92 $40,605 - $63,431
-8,009 Reduced 7.12%
104,437 $670,000
Q3 2017

Nov 14, 2017
SELL
$5.4 - $8.47 $61,657 - $96,710
-11,418 Reduced 9.22%
112,446 $860,000
Q2 2017

Aug 14, 2017
BUY
N/A
23,897 Added 23.9%
123,864 $881,000
Q1 2017

Nov 14, 2017
BUY
N/A
99,967
99,967 $387,000

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email